Supplementary Data from Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

Supplementary Table 1: Number of plasma samples included in the study Supplementary Table 2: Association of toxicity with treatment response Supplementary Table 3: Differentially expressed cytokines in patients with severe irAEs compared to those with no-severe irAEs at PRE in Cohort 2 Supplementary Table 4: Differentially expressed cytokines in patients with severe irAEs compared to those with no-severe irAEs at EDT in Cohort 2 Supplementary Table 5: Univariate analysis of cytokine expression and association with overall survival Supplementary Table 6: Univariate analysis of cytokine expression and association with RECIST response Supplementary Figure 1: Distribution of relative fluorescence intensity units of 65 circulating cytokines in plasma collected from 98 melanoma patients (cohorts 1 and 2) prior to therapy initiation. Supplementary Figure 2: Hierarchical clustering of cytokine expression profiles in cohorts 1 and 2.